Top Page
IVD Medical Holding Limited
(1931)
IVD Medical Holding Limited (1931) vs. iShares MSCI Hong Kong ETF (EWH)
IVD Medical Holding Limited Business Overview & Revenue Model
IVD Medical Holding Limited Financial Statement Overview
| Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 3.16B | 3.09B | 2.75B | 2.73B | 2.43B |
| Gross Profit | 751.17M | 671.70M | 608.14M | 566.27M | 476.17M |
| EBITDA | 475.96M | 397.93M | 349.66M | 286.17M | 250.04M |
| Net Income | 260.42M | 238.16M | 210.00M | 174.54M | 158.72M |
Balance Sheet | |||||
| Total Assets | 5.52B | 4.79B | 4.31B | 4.37B | 3.91B |
| Cash, Cash Equivalents and Short-Term Investments | 1.86B | 1.24B | 1.04B | 841.78M | 794.74M |
| Total Debt | 755.97M | 344.32M | 349.92M | 427.65M | 421.80M |
| Total Liabilities | 1.76B | 1.40B | 1.16B | 1.37B | 1.05B |
| Stockholders Equity | 3.71B | 3.34B | 3.15B | 2.98B | 2.85B |
Cash Flow | |||||
| Free Cash Flow | 88.69M | 251.92M | 215.39M | 137.88M | 144.87M |
| Operating Cash Flow | 140.29M | 292.42M | 249.67M | 163.11M | 170.49M |
| Investing Cash Flow | -57.80M | -77.58M | 60.54M | -27.88M | -196.00M |
| Financing Cash Flow | 395.13M | -19.45M | -191.29M | -66.29M | -63.24M |
IVD Medical Holding Limited Technical Analysis
IVD Medical Holding Limited Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
78 Outperform | $59.41B | 7.78 | 9.19% | 3.82% | -3.94% | -23.48% | |
72 Outperform | HK$10.53B | 30.60 | 6.72% | 1.95% | 33.41% | 26.81% | |
67 Neutral | HK$15.00B | 48.99 | 7.40% | 0.99% | 0.67% | -1.75% | |
66 Neutral | $69.48B | 9.95 | 6.08% | 2.52% | 3.27% | 12.87% | |
60 Neutral | HK$18.14B | 5.30 | -4.00% | 3.33% | 10.16% | -17.39% | |
47 Neutral | HK$907.24M | ― | -31.49% | ― | -7.28% | -46.18% |
IVD Medical Holding Limited Corporate Events
IVD Medical Holding Limited has announced the establishment of a global enhanced Ethereum vault as part of its strategic upgrade. This initiative aims to integrate the Ethereum ecosystem into their operations, enhancing the efficiency of medical innovative drug research and development. By designating Ethereum as a core reserve asset, the company seeks to improve capital flow, asset turnover, and risk hedging, aligning with the global trend of institutional cryptocurrency asset allocation. This move is expected to revolutionize the capital efficiency and globalization process of the medical innovative drugs industry, creating value for ecosystem participants.
IVD Medical Holding Limited has entered into a strategic cooperation framework with HashKey Group to accelerate its global enhanced Ethereum vault strategy. This partnership will enable IVD Medical to efficiently manage its Ethereum reserves, optimize transaction costs, and explore the integration of cryptocurrency assets with real economy assets, particularly in the realm of innovative drug intellectual property rights. The collaboration is expected to enhance the company’s operations by providing access to HashKey’s global market resources, technical support, and compliance ecosystem, thus driving the global development of medical innovative drugs.
IVD Medical Holding Limited has announced the completion of its first reserve purchase of Ethereum (ETH) as part of its ‘Global Enhanced ETH Vault’ strategy. The company acquired 5,190 ETH at an average price of HK$28,798.21, totaling HK$149.47 million, through HashKey Exchange. This strategic move is aimed at strengthening the company’s reserves, attracting institutional investors, and enhancing risk resilience by integrating healthcare assets with the decentralized finance ecosystem.
IVD Medical Holding Limited has announced the establishment of a global enhanced Ethereum vault as part of its strategic upgrade. This initiative aims to integrate the company’s medical innovative drug assets with the Ethereum ecosystem, enhancing capital flow and asset turnover while reducing systemic risk. The strategy involves using Ethereum as a core reserve asset, aligning with global trends in cryptocurrency asset allocation. This move is expected to improve the efficiency of medical drug research and development and facilitate a transition to a Web3 financial paradigm.
IVD Medical Holding Limited has announced a strategic cooperation with BGI Co-Win to establish the IVD-BGI Co-Win Innovative Drug Intellectual Property Tokenization Fund. This initiative aims to invest in projects under the company’s NewCo + RWA Web3 Exchange Ecosystem model, enhancing its global presence in the medical innovative drug sector. The collaboration is expected to strengthen IVD Medical’s role in reshaping the global value chain of medical innovative drug assets, although the agreement’s specific terms are yet to be finalized.
IVD Medical Holding Limited has announced a significant brand upgrade, including a new slogan, logo, and official website, as part of its strategic transformation towards becoming a ‘Global Medical Innovation Value Chain – Decentralized Scientific Ecosystem Builder.’ This rebranding aligns with their ‘NewCo + RWA’ Web3 exchange ecosystem strategy and emphasizes their focus on innovation, verification, and development, potentially enhancing their market positioning and stakeholder engagement.
IVD Medical Holding Limited announced that its subsidiary, Vastec Medical Equipment (Shanghai) Co., Ltd., has successfully secured a sustainability-linked revolving syndicated loan. This financial development, involving hundreds of millions of RMB, is expected to enhance the company’s operational capabilities and strengthen its position in the medical equipment industry by aligning with sustainability goals.
IVD Medical Holding Limited has announced significant progress in its strategic initiatives, including the establishment of a wholly-owned subsidiary in New York and the launch of a US stablecoin license application. These developments are part of the company’s broader strategy to implement the IVDNewCo Exchange Ecosystem, which aims to tokenize real-world medical assets and create a compliant financial infrastructure for stablecoin issuance and trading. The recent signing of the Genius Act by the US President and the introduction of Hong Kong’s Stablecoins Ordinance are expected to accelerate the development of the global stablecoin market, potentially benefiting IVD Medical’s operations and positioning in the industry.
IVD Medical Holding Limited has announced the launch of ‘IVDNewCo Exchange’, a pioneering Web3 exchange ecosystem aimed at transforming the pharmaceutical industry by integrating real-world asset tokenization, blockchain transactions, and stablecoin mechanisms. This initiative seeks to enhance the liquidity and financing efficiency of global medical innovative drug assets, addressing industry challenges like low financing efficiency and poor asset liquidity, while enabling 24/7 global transactions.
IVD Medical Holding Limited has announced plans for a dual primary listing on the Nasdaq Stock Market in the United States, aiming to broaden its shareholder base and enhance its corporate image. However, the company has issued a profit warning, expecting a significant decrease in profit for the first half of 2025 due to increased administrative and distribution expenses.
IVD Medical Holding Limited has announced the composition of its board of directors and their respective roles and functions. This announcement provides clarity on the governance structure of the company, which is crucial for stakeholders to understand the leadership and oversight within the organization.
IVD Medical Holding Limited announced significant changes in its board composition, with the retirement of Mr. Ho Kuk Sing as chairman and CEO effective July 1, 2025. He will continue as a consultant to ensure a smooth transition. The company has initiated a search for his successor, considering both internal and external candidates. Additionally, the company appointed three new independent non-executive directors, Ms. Tai Yang, Mr. Xu Da, and Mr. Zhang Jianlei, who will assume their roles on the same date. These changes are expected to bring fresh perspectives and strengthen the company’s governance structure.
IVD Medical Holding Limited announced the results of its Annual General Meeting held on June 30, 2025, where all proposed resolutions were passed. Key resolutions included the approval of financial statements, re-election of directors, and the adoption of a new share award scheme. The decisions reflect the company’s strategic direction and may impact its market operations and stakeholder interests.
IVD Medical Holding Limited has announced its upcoming Annual General Meeting scheduled for June 30, 2025, in Hong Kong. The meeting will address several key resolutions, including the approval of the 2024 financial statements, re-election of directors, and the authorization of share repurchase and issuance mandates. These resolutions are crucial for the company’s governance and strategic flexibility, potentially impacting its market operations and shareholder value.